DOLUTEGRAVIR TABLETS 50MG
Generic Name: Dolutegravir
Strength: 50mg
Dosage Form: Tablet
Medicine Class: Integrase Strand Transfer Inhibitor (INSTI) / Antiretroviral
Manufacturer/Brand: Natco / Xapavir 50 mg
Dolutegravir Tablets 50mg is an antiretroviral medicine used to treat human immunodeficiency virus type 1 (HIV-1) infection. It belongs to the integrase strand transfer inhibitor (INSTI) class and is generally used in combination with other antiretroviral medicines to control HIV infection and reduce the amount of virus in the blood.
Dolutegravir Tablets 50mg contains dolutegravir, an antiretroviral medicine belonging to the integrase strand transfer inhibitor (INSTI) class. It is used as part of combination antiretroviral therapy for managing HIV-1 infection.
The medicine helps control HIV by interfering with an enzyme the virus needs to reproduce. It reduces viral activity and helps support immune system function but does not cure HIV.
Dolutegravir Tablets 50mg may be prescribed to:
Treat HIV-1 infection in adults as part of combination antiretroviral therapy.
Manage HIV infection in people who are starting antiretroviral treatment.
Treat HIV infection in certain individuals who have previously received antiretroviral treatment, depending on their treatment history and resistance profile.
Maintain viral suppression in eligible individuals when switching to an approved dolutegravir-based treatment regimen.
The appropriate treatment combination, dose, and duration should be determined by a healthcare professional based on the patient's medical history and HIV treatment requirements.
Dolutegravir works by blocking HIV integrase, an enzyme that the virus needs to insert its genetic material into human cells.
By preventing this integration process, the medicine reduces the virus's ability to reproduce and spread within the body. When taken consistently with the other prescribed antiretroviral medicines, it helps reduce HIV viral load and supports immune system function.
The time required to achieve viral suppression varies depending on the individual's condition, treatment history, and response to therapy.
Take Dolutegravir Tablets 50mg exactly as prescribed by your healthcare professional.
The tablet is generally taken once daily, although some individuals may require twice-daily administration depending on treatment history and other medicines.
It can generally be taken with or without food.
Take the medicine at approximately the same time each day.
Swallow the tablet with water.
Follow your doctor's instructions regarding the timing of antacids, iron supplements, calcium supplements, and other mineral-containing products.
Do not skip doses, change the prescribed dose, or stop treatment without consulting your doctor.
If you miss a dose, take it when you remember unless it is nearly time for your next dose. Do not take a double dose to compensate for a missed dose.
Consistent use is important for maintaining control of HIV infection and reducing the risk of developing drug resistance.
Before starting Dolutegravir Tablets 50mg, inform your doctor or pharmacist about your medical history and all medicines, supplements, and herbal products you use.
Particular caution may be required if you have:
Liver disease: People with existing liver conditions may require additional monitoring during treatment.
Kidney problems: Inform your doctor about any history of kidney disease, as your overall treatment may require medical assessment.
Previous allergic reactions: Tell your doctor if you have experienced an allergic reaction to dolutegravir or any ingredients in the formulation.
Mental health conditions: Inform your healthcare professional about a history of depression or other significant mental health concerns.
Previous HIV treatment or resistance: Your treatment history may influence whether dolutegravir is an appropriate option.
Important medicine interactions include:
Rifampicin: This medicine can reduce dolutegravir levels and may require an adjustment to the treatment regimen.
Antacids and mineral supplements: Products containing aluminium, magnesium, calcium, or iron may affect dolutegravir absorption. Their administration may need to be separated or adjusted according to the product instructions.
Metformin: Dolutegravir can increase metformin levels in the blood, potentially requiring dose adjustment and monitoring.
Certain anticonvulsants: Medicines such as carbamazepine, phenytoin, and phenobarbital may reduce dolutegravir concentrations.
Check all possible medicine interactions with your doctor or pharmacist before starting treatment.
Dolutegravir may be used during pregnancy as part of HIV treatment when recommended by a healthcare professional. Available evidence has not shown an increased risk of neural tube defects associated with dolutegravir use around conception. Treatment decisions should consider the individual's HIV status and pregnancy-related medical requirements.
Dolutegravir can pass into breast milk. However, breastfeeding recommendations for people living with HIV vary between countries because of differences in guidance regarding HIV transmission and infant feeding.
If you are pregnant, planning a pregnancy, or breastfeeding, consult your doctor before starting or changing treatment. Do not discontinue antiretroviral therapy without medical advice.
Like all medicines, Dolutegravir Tablets 50mg can cause side effects, although not everyone experiences them.
Commonly reported side effects may include:
Headache
Nausea
Diarrhoea
Difficulty sleeping (insomnia)
Dizziness
Fatigue
Seek prompt medical attention if you develop a severe skin rash, facial or throat swelling, breathing difficulties, yellowing of the skin or eyes, dark urine, or other symptoms suggesting a serious allergic reaction or liver problem. Significant changes in mood or unusual thoughts should also be discussed with a healthcare professional.
This is not a complete list of side effects or warnings. Please refer to the product packaging and patient information leaflet supplied with your medicine for complete information and speak with your doctor or pharmacist if you have concerns.
Store Dolutegravir Tablets 50mg according to the instructions shown on the original product packaging.
Keep the tablets in their original packaging.
Protect the medicine from excessive heat and moisture.
Keep the container properly closed when not in use.
Keep out of reach of children.
Do not use the medicine after its expiry date.
Storage conditions may vary depending on the manufacturer and product packaging.
Dolutegravir Tablets 50mg is used to treat HIV-1 infection as part of combination antiretroviral therapy. It helps reduce the amount of HIV in the blood and supports immune system function.
Dolutegravir begins working against HIV after treatment starts, but achieving viral suppression takes time. The response varies between individuals and is monitored through regular HIV viral load testing.
Yes. Dolutegravir tablets can generally be taken with or without food. However, certain antacids and mineral supplements may affect its absorption and require specific timing instructions.
For many adults, the usual dose is 50mg once daily. Some individuals may require 50mg twice daily depending on previous treatment, drug resistance, or interactions with other medicines. The prescribed dose should always be followed.
No. Dolutegravir does not cure HIV. It helps control viral replication and reduce viral load when used consistently with the prescribed antiretroviral treatment combination.
No. An undetectable viral load does not mean HIV has been cured. Continue treatment as prescribed and consult your doctor before making any changes to your medication.
Yes. Dolutegravir is commonly used with other antiretroviral medicines as part of combination HIV treatment. The combination should be selected by a healthcare professional based on treatment history, resistance, and possible drug interactions